UPDATES IN “LIPIDS MANAGEMENT” GUIDELINES
- Author:
TAI E Shyong
- Publication Type:Journal Article
- Keywords:
Lipids;
Statin;
Cardiovascular risk
- From:The Singapore Family Physician
2016;42(2):16-18
- CountrySingapore
- Language:English
-
Abstract:
A recent change in the paradigm of lipids management
relates to the use of low-density-lipoprotein cholesterol
(LDL-C) goals to direct the dose and type of statin
prescribed. In place of LDL-C goals, the intensity of statin
therapy (based on the ability of a particular dose of a drug to
lower LDL-C) is now recommended by the American
College of Cardiology and the American Heart Association
to be calibrated to the level of cardiovascular risk. The role
of niacin and fenofibrate has largely declined, although an
emerging role for fenofibrate in the treatment and
prevention of microvascular complications in patients with
diabetes mellitus is emerging and presents interesting
potential to extend the benefits of this class of drugs. Finally,
the benefits of lipid lowering in patients with chronic kidney
disease has now been demonstrated in randomised
controlled trials and could probably be represented in the
algorithms for risk stratification in future.
